Skip to Content

Ilumya Approval History

FDA Approved: Yes (First approved March 20, 2018)
Brand name: Ilumya
Generic name: tildrakizumab-asmn
Dosage form: Injection
Company: Sun Pharmaceutical Industries Inc.
Treatment for: Plaque Psoriasis

Ilumya (tildrakizumab-asmn) is a humanized, anti-IL-23p19 monoclonal antibody for the treatment of moderate-to-severe plaque psoriasis.

Development History and FDA Approval Process for Ilumya

DateArticle
Mar 21, 2018Approval FDA Approves Ilumya (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Psoriasis
May 24, 2017Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application (BLA) For Tildrakizumab

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide